To the full analysis
Basilea Pharmaceutica stock: growth
BSLN.SWBasilea Pharmaceutica reported $278.95M in revenue for fiscal 2025, up 11.4% on the prior year, up 12.7% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
20.1%
per year from 2006 to 2025, per share 17.2%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 12.7% | 16.0% | 20.1% |
| Revenue per share | 8.9% | 13.8% | 17.2% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $8.62M | −$102.2M | −$88.93M |
| 2007 | $9.48M | −$152.22M | −$102.65M |
| 2008 | $14.37M | −$172.27M | −$158.9M |
| 2009 | $32.2M | −$144.92M | −$139.56M |
| 2010 | $138.7M | $129.11M | $126.51M |
| 2011 | $79.4M | −$69.19M | −$103.11M |
| 2012 | $70.02M | −$63.65M | $176.27M |
| 2013 | $49.15M | −$39.63M | −$72.7M |
| 2014 | $51.01M | −$49.87M | −$87.27M |
| 2015 | $63.4M | −$73.94M | −$82.57M |
| 2016 | $79.2M | −$61.56M | −$90.5M |
| 2017 | $121.85M | −$23.24M | $21.97M |
| 2018 | $159.1M | −$37.63M | −$95.58M |
| 2019 | $161.3M | −$26.91M | −$77.11M |
| 2020 | $153.19M | −$17.67M | −$67.69M |
| 2021 | $177.79M | −$8.2M | −$39.47M |
| 2022 | $177.36M | $14.58M | $4.5M |
| 2023 | $189.21M | $12.54M | $15.86M |
| 2024 | $250.31M | $93.13M | $87.2M |
| 2025 | $278.95M | $48.25M | $71.09M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 21 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.